Licensing Agreement with Takeda for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

Six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction

Announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients

Submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients


Completes enrolment of its AlloCSC-01 Phase I/II study in acute myocardial infarction

AlloCSC-01 Phase I Data Presented at the Congress of the European Society of Cardiology 

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial

Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial

TiGenix NV successfully places EUR 25 million convertible bonds


European Medicines Agency renews Marketing Authorization for ChondroCelect

TiGenix announces development plan for Cx611 in early rheumatoid arthritis and severe sepsis

TiGenix sells manufacturing facility to PharmaCell


TiGenix secures Euro 10 million debt financing through Kreos Capital

TiGenix raises Euro 12 million through private placement with strategic investor, Grifols

TiGenix raises Euro 6.5 million in private placement

TiGenix reports positive Phase IIa trial results for Cx611 in refractory rheumatoid arthritis


Cx601 Phase III in perianal fistulas enrolls first patients

Cx611 Phase IIa in rheumatoid arthritis completes enrollment

Cx621 Phase I successfully concluded


TiGenix obtains EUR 5 million financing facility for phase III fistula program in Crohn's disease

Positive 5 year data on ChondroCelect published in AJSM

TiGenix closes EUR 15.2 million rights offering


Spin-out of drug discovery platform into Arcarios

Commercial launch of ChondroCelect in Europe


ChondroCelect approved by EMA

TiGenix receives positive CHMP opinion for ChondroCelect


Initial Public Offering, raising a total of €46m


Incorporation of TiGenix

You have added 0 page(s) to your PDF. Download your PDF